Beta-citronellene is a monoterpene hydrocarbon found in various essential oils, including lemongrass, citronella, and eucalyptus. It is a colorless liquid with a characteristic citrus-like aroma. The synthesis of beta-citronellene can be achieved through different methods, including the reaction of citronellal with Grignard reagents or the catalytic hydrogenation of citronellal. Beta-citronellene exhibits various biological activities, such as antifungal, antibacterial, and insecticidal properties. Its effects on insects have led to its investigation as a potential natural insecticide. Furthermore, beta-citronellene has been explored for its potential use in the food and fragrance industries due to its pleasant aroma and flavor. Its unique chemical structure and biological activities make it an interesting compound for research and development.'
beta-citronellene: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 17090 |
| CHEMBL ID | 2268551 |
| MeSH ID | M0525752 |
| Synonym |
|---|
| dihydromyrcene |
| 1,6-octadiene, 3,7-dimethyl- |
| citronellene |
| 3,7-dimethyl-1,6-octadiene |
| einecs 219-433-3 |
| 3,7-dimethylocta-1,6-diene |
| 2436-90-0 |
| NCGC00249153-01 |
| unii-ls5la2bug0 |
| ec 219-433-3 |
| ls5la2bug0 , |
| NCGC00259593-01 |
| tox21_202044 |
| dtxcid809234 |
| cas-2436-90-0 |
| dtxsid8029234 , |
| A817251 |
| 3,7-dimethyl-octa-1,6-diene |
| 128241-35-0 |
| AKOS006230490 |
| .beta.-citronellene |
| beta-citronellene |
| CHEMBL2268551 |
| 2,6-dimethyl 2,7-octadiene |
| (+)-beta-citronellene |
| FT-0761924 |
| FT-0772372 |
| Q27283156 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The optimized formulation was further evaluated for in vitro drug release, confocal microscopy and in vivo pharmacokinetic study." | ( Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment. Ahad, A; Ali, A; Aqil, M; Imam, SS; Kamran, M; Sultana, Y, 2016) | 0.43 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "15 times improvement in bioavailability of olmesartan with respect to the control formulation in Wistar rats." | ( Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment. Ahad, A; Ali, A; Aqil, M; Imam, SS; Kamran, M; Sultana, Y, 2016) | 0.43 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 35.9706 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 21.3196 | 0.0010 | 24.5048 | 61.6448 | AID743215 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 75.0064 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.84) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||